Absci Corporation announced two senior executives to lead its drug creation team: Christine Lemke, DVM, MBA, SVP of Portfolio & Growth Strategy, and Christian Stegmann, Ph.D., SVP of Drug Creation. Dr. Lemke previously served as Head of Global Corporate Development at Ferring International Center SA. A seasoned international executive, she brings substantial corporate development and operations expertise to Absci.

For global biopharmaceutical companies, including Bayer, Shire, and Takeda, Dr. Lemke delivered multiple global, transformative strategic projects. Her experience in nearly every aspect of drug discovery and development will shape Absci's R&D strategy with an emphasis on bringing life-changing medicines to patients. Dr. Stegmann is an accomplished R&D leader with a track record of building teams that successfully bring novel molecules into clinical development.

Dr. Stegmann previously served as the VP of Research and Non-clinical Development at CSL Vifor, where he built a highly innovative R&D portfolio in nephrology and iron deficiency. Prior to that, he held various R&D leadership roles at Bayer, most recently as Senior Director of its Precision Cardiology Laboratory, leading a collaboration with the Broad Institute of MIT and Harvard.